Real-world considerations for selecting antiplatelet therapy in high-risk ACS patients: putting evidence into clinical practice

This educational programme is accredited by EBAC for one hour of External CME credit - Programme supported by an unrestricted educational grant from ASTRAZENECA



Click here to watch the VIDEO

Learning Objectives

  • To appreciate new developments in ACS risk stratification and develop appropriate treatment strategies to improve outcomes for high-risk ACS patients
  • To understand the issues surrounding short- versus long-term antiplatelet therapy
  • To discuss best practices in antiplatelet therapy from both case-based and guidelines-based perspectives

Presentations available when logged in:

  • Reducing cardiovascular risk and death - The importance of risk stratification in ACS
  • Optimal duration for oral antiplatelet therapy - Treating the stent versus treating the patient with ACS
  • Take-home message